Business
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
Company’s oral synthetic psilocybin program advances within significantly improved regulatory environmentMELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April 18, 2026, titled, “Accelerating Medical Treatments for Serious Mental Illness.” The Company believes its
About this update from Incannex Healthcare Inc.
[{"type":"image","alt":"Incannex Healthcare","displaySize":"","headline":null,"caption":"Incannex Healthcare","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I8iSgbDVR4wwesVYH5DtzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcw/https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7","width":300,"height":50}},"lazy":false},{"type":"text","content":"Company’s oral synthetic psilocybin program advances within significantly improved regulatory environment","length":105,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April 18, 2026, titled, “Accelerating Medical Treatments for Serious Mental Illness.” The Company believes its PSX-001 development program aligns with the goals outlined in the Executive Order and believes the data demonstrated to date, along with a more amenable regulatory environment, may provide significant hope for those suffering from anxiety disorders.","length":645,"tagName":"p"},{"type":"text","content":"“We agree with the Administration’s recognition that the mental health crisis in America demands a new level of regulatory urgency and scientific ambition,” commented Incannex CEO Joel Latham. ”For years, patients suffering from debilitating anxiety disorders have had limited options, particularly for those who fail first-line treatments. PSX-001, our oral synthetic psilocybin therapeutic for Generalized Anxiety Disorder, is designed for exactly these patients and this Executive Order represents a meaningful step toward ensuring that novel, evidence-based therapies like ours can reach them without unnecessary delay.”","length":624,"tagName":"p"},{"type":"text","content":"PSX-001: Rigorous Science, Compelling Data, a Clear Path Forward","length":64,"tagName":"p"},{"type":"text","content":"PSX-001 is an oral, fixed-dose synthetic psilocybin formulation in development for Generalized Anxiety Disorder (GAD), a condition affecting an estimated 280 million people globally and approxi...